Lori Elizabeth Mochan
Directeur/Bestuurslid bij NIGHTSTAR THERAPEUTICS PLC
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Helen Elizabeth Hanby | F | 58 |
Tungsten Bidco Ltd.
Tungsten Bidco Ltd. Financial ConglomeratesFinance Founded in 2019, Tungsten Bidco Ltd. is a British company that functions as an investment holding company. Part of Biogen, Inc., the company is based in Maidenhead, UK.
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | - |
Nicole Reichman | F | 52 |
Amicus Therapeutics UK Ltd.
Amicus Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Amicus Therapeutics, Inc., Amicus Therapeutics UK Ltd. is a company that focuses on delivering high-quality therapies for persons living with rare and orphan diseases. The company is based in Gerrards Cross, UK. The employees of Amicus crafted a belief statement that encompasses their core values and reminds them of the reason they do what they do every day. The statement outlines the fundamental beliefs that are crucial to understanding the passion and commitment behind Amicus. The British company believes in the fight to remain at the forefront of therapies for rare and orphan diseases, supporting the disease communities and their families, and fostering teamwork and respect for each individual's contribution. | 7 jaar |
Bradley Campbell | M | 48 |
Amicus Therapeutics UK Ltd.
Amicus Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Amicus Therapeutics, Inc., Amicus Therapeutics UK Ltd. is a company that focuses on delivering high-quality therapies for persons living with rare and orphan diseases. The company is based in Gerrards Cross, UK. The employees of Amicus crafted a belief statement that encompasses their core values and reminds them of the reason they do what they do every day. The statement outlines the fundamental beliefs that are crucial to understanding the passion and commitment behind Amicus. The British company believes in the fight to remain at the forefront of therapies for rare and orphan diseases, supporting the disease communities and their families, and fostering teamwork and respect for each individual's contribution. | - |
Paula Cobb | F | 51 |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | - |
Jane Elizabeth Machin | F | 56 |
Amicus Therapeutics UK Ltd.
Amicus Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Amicus Therapeutics, Inc., Amicus Therapeutics UK Ltd. is a company that focuses on delivering high-quality therapies for persons living with rare and orphan diseases. The company is based in Gerrards Cross, UK. The employees of Amicus crafted a belief statement that encompasses their core values and reminds them of the reason they do what they do every day. The statement outlines the fundamental beliefs that are crucial to understanding the passion and commitment behind Amicus. The British company believes in the fight to remain at the forefront of therapies for rare and orphan diseases, supporting the disease communities and their families, and fostering teamwork and respect for each individual's contribution. | - |
Ben Michael Paul Stockham | M | 52 |
Amicus Therapeutics UK Ltd.
Amicus Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Amicus Therapeutics, Inc., Amicus Therapeutics UK Ltd. is a company that focuses on delivering high-quality therapies for persons living with rare and orphan diseases. The company is based in Gerrards Cross, UK. The employees of Amicus crafted a belief statement that encompasses their core values and reminds them of the reason they do what they do every day. The statement outlines the fundamental beliefs that are crucial to understanding the passion and commitment behind Amicus. The British company believes in the fight to remain at the forefront of therapies for rare and orphan diseases, supporting the disease communities and their families, and fostering teamwork and respect for each individual's contribution. | 6 jaar |
Detlef Wolff | M | 59 |
Amicus Therapeutics UK Ltd.
Amicus Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Amicus Therapeutics, Inc., Amicus Therapeutics UK Ltd. is a company that focuses on delivering high-quality therapies for persons living with rare and orphan diseases. The company is based in Gerrards Cross, UK. The employees of Amicus crafted a belief statement that encompasses their core values and reminds them of the reason they do what they do every day. The statement outlines the fundamental beliefs that are crucial to understanding the passion and commitment behind Amicus. The British company believes in the fight to remain at the forefront of therapies for rare and orphan diseases, supporting the disease communities and their families, and fostering teamwork and respect for each individual's contribution. | 6 jaar |
Christian Ruppenthal | M | - |
Amicus Therapeutics GmbH
Amicus Therapeutics GmbH BiotechnologyHealth Technology Part of Amicus Therapeutics, Inc., Amicus Therapeutics GmbH is a German biotechnology company that develops therapies for rare and orphan diseases. The company is based in Munich, Germany. The CEOs are Lori Elizabeth Mochan, Christian Ruppenthal, Anita Jane Clifford. The company was founded in 2002. | - |
Anita Jane Clifford | F | - |
Amicus Therapeutics GmbH
Amicus Therapeutics GmbH BiotechnologyHealth Technology Part of Amicus Therapeutics, Inc., Amicus Therapeutics GmbH is a German biotechnology company that develops therapies for rare and orphan diseases. The company is based in Munich, Germany. The CEOs are Lori Elizabeth Mochan, Christian Ruppenthal, Anita Jane Clifford. The company was founded in 2002. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigd Koninkrijk | 7 | 77.78% |
Duitsland | 2 | 22.22% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Lori Elizabeth Mochan
- Persoonlijk netwerk